Search
Fucoxanthin
go.drugbank.com/drugs/DB15462InvestigationalFucoxanthin isis a marine carotenoid mainly found in brown algae, giving them a brown or olive-green color. … A clinical trial of fucoxanthin against non-alcoholic fatty liver disease is ongoing.
LJP 1082
go.drugbank.com/drugs/DB05446ExperimentalThe target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I. … LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1.
Categories: Compounds used in a research, industrial, or household settingZYCOV-D
go.drugbank.com/drugs/DB15892ExperimentalThe vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of interest[L16503]. … As of August, 2020 the candidate is in Phase II clinical trials[A219758].
Amcipatricin
go.drugbank.com/drugs/DB12333InvestigationalAmcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment … SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone
Chlorotoxin I-131
go.drugbank.com/drugs/DB05462InvestigationalIt is a synthetic version of a neurotoxin isolated from the venom of the Giant Yellow Israeli scorpion Leiurus quinquestriatus. … The synthetic version of this peptide has been manufactured and covalently linked to iodine 131 as a means of targeting radiation to tumor cells in the treatment of brain cancer.
AVR118
go.drugbank.com/drugs/DB04979InvestigationalAVR118 represents a new type of biopolymer chemistry that also possesses novel immunomodulator activity. … This non-toxic peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human
Lufotrelvir
go.drugbank.com/drugs/DB16514InvestigationalPF-07304814, developed by Pfizer, was first identified during the SARS outbreak in 2002-2003; it was subsequently shelved as the outbreak was controlled[L31728]. … PF-07304814 is a small molecule prodrug that targets the 3CL<sup>pro</sup> protease (M<sup>pro)</sup>, which is used by viruses like SARS-CoV-2 to assemble and multiply[L31718].
Basic Fibroblast Growth Factor
go.drugbank.com/drugs/DB14131InvestigationalBasic Fibroblast Growth Factor (bFGF) is a single-chain polypeptide growth factor that plays a significant role in the process of wound healing and is a potent inducer of physiologic angiogenesis. … The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages.
Synonyms: KCB-1, Basic fibroblast growth factor, recombinant human, KCB-1INO-4800
go.drugbank.com/drugs/DB15693Investigational[A214475] A Phase 1 clinical trial for INO-4800 in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021. … INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19.
CZEN 002
go.drugbank.com/drugs/DB05479ExperimentalIt appears that CZEN-002 works on a receptor in yeast that has yet to be identified. … It has also been shown to kill Candida albicans (C. albicans), a single-celled fungal organism that causes a variety of infections, including vaginitis.